May 05, 2021 / 04:10PM GMT
Asthika Sarith Goonewardene - Truist Securities, Inc., Research Division - Research Analyst
Hello, everyone, and welcome to our next session. My name is Asthika Goonewardene. We are thrilled to have the folks from Iovance with us on this installment of the Truist Securities Life Sciences Summit.
From the company, we have Maria Fardis, President and CEO, joining us today. Maria, welcome. It's a pleasure to have you here, first time on our platform.
Maria Fardis -
Thank you for the invite. Much appreciate the initiation of the coverage as well.
Asthika Sarith Goonewardene - Truist Securities, Inc., Research Division - Research Analyst
Yes. I might as well mention that. So we actually just freshly initiated coverage on Iovance with a buy just on Monday. We are definitely just about the deal space, and we'll talk about that more. Before we start, let me read out my disclosure, and I'm going to hand over to Maria to do some introductions to the company.
So this call is arranged by Truist Securities Research for
Iovance Biotherapeutics Inc at Truist Securities Life Sciences Summit (May Series) Transcript
May 05, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers